<DOC>
	<DOCNO>NCT01049412</DOCNO>
	<brief_summary>Comparison blood glucose level patient Type 1 diabetes take new basal insulin analog take insulin glargine</brief_summary>
	<brief_title>A Study Patients With Type 1 Diabetes</brief_title>
	<detailed_description>Prestudy treatment patient enter study daily insulin glargine along mealtime insulin . Patients continue use mealtime insulin throughout study . The study consist 16 week treatment 4 week follow-up . The 16 week treatment consist two 8-week period ( Periods 1 2 ) patient receive insulin glargine 8 week LY2605541 8 week random sequence . During 4-week follow-up period , patient return insulin glargine another basal insulin recommend investigator .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes mellitus ( T1DM ) least 1 year use insulin glargine least 6 month maximum daily dose 1 U/kg . HbA1c great 10.5 % randomization Body mass index ( BMI ) 19 45 kg/m2 Capable willing prepare inject insulin syringe , monitor blood glucose , complete study diary , receptive diabetes education , comply study requirement , receive telephone call treatment Women childbearing potential must test negative pregnancy receive treatment agree use reliable birth control complete followup Twice daily use insulin glargine within 30 day prior study Use oral injectable medication intend treatment diabetes mellitus insulin 3 month prior study Use insulin pump More 1 episode severe hypoglycemia within 3 month prior study , currently diagnose hypoglycemia unawareness 2 emergency room visit hospitalization due poor glucose control 6 month precede study Known hypersensitivity allergy study insulins excipients Blood transfusion severe blood loss within 3 month prior study know hemoglobinopathy , hemolytic anemia , sickle cell anemia , traits hemoglobin abnormality know interfere HbA1c methodology Irregular sleep/wake cycle Pregnant intend become pregnant study Women breastfeed Use prescription overthecounter medication promote weight loss within 3 month prior study Current participation weight loss program plan study Use chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy currently within 4 week prior study Cardiac disease mark impact physical functioning Clinically significant ECG abnormality screen Fasting triglyceride great 500 mg/dL Liver disease History renal transplantation , current renal dialysis , creatinine great 2.0 mg/dL ( 177 Î¼mol/L ) Malignancy basal cell squamous cell skin cancer , currently within last 5 year Treatment antibodybased therapy within 6 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>